Results 71 to 80 of about 66,268 (303)

Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. [PDF]

, 2016
BACKGROUND: Apart from baseline glycated hemoglobin (HbA1c), little is known about clinical parameters that affect glycemic response to a dipeptidyl peptidase-4 (DPP4) inhibitor when used in routine clinical practice. We aimed to use a large primary care
Donnelly, Richard, Idris, Iskandar, Mamza, Jil, Mehta, Rajnikant   +3 more
core   +1 more source

The role of dipeptidyl peptidase-4 inhibitors

BMJ, 2012
Will be clearer once ongoing trials are complete Type 2 diabetes is a progressive disease and greater treatment intensity is needed over time to control increasingly abnormal glucose concentrations.1 In the linked article (doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits ...
Lasserson, D, Mant, J
openaire   +4 more sources

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Janie E. Rogers, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +9 more
wiley   +1 more source

Synthetic Strategies for Activity‐Based Probes to Decode Ubiquitin‐Like Modifiers

Chemistry – A European Journal, EarlyView.
ABSTRACT Ubiquitin‐like proteins (Ubls) such as SUMO, NEDD8, ISG15, URM1, UFM1, FAT10, ATG8/ATG12, and FUBI are essential regulators of cellular homeostasis, controlling processes from protein stability and trafficking to immune signaling and autophagy.
Saibal Chanda, Alan Pham, SreeNidhi Karnati, Natalia Soto Rodriguez, Alyssa Toner, Wenshe Ray Liu   +5 more
wiley   +1 more source

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]

, 2018
Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo, Baldi, Ileana, Bossi, Antonio Carlo, Bottigliengo, Daniele, Cavalot, Franco, D'Angelo, Federica, DARWIN-T2D Network, Fadini, Gian Paolo, Morano S., Raffaella Buzzetti, Zatti, Giancarlo   +10 more
core   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

The ester hydrolytic and synthetic activities of X-prolyl dipeptidyl peptidase from Streptococcus thermophilus : a thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Biochemistry at Massey University, New Zealand [PDF]

, 2003
X-prolyl dipeptidyl peptidase (EC 3.4.14.11), or PepX, is a dipeptidase found in most dairy lactic acid bacteria that hydrolyses N-terminal dipeptides from larger peptides where proline is the residue penultimate to the scissile bond.
Bennett, Matthew David
core  

A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation

Food Chemistry International, EarlyView.
Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee, Tien‐Fen Kuo, Chun‐Yen Yang, Greta Yang, Wen‐Chin Yang   +4 more
wiley   +1 more source

Henoch–Schönlein purpura induced by sitagliptin: A case report

SAGE Open Medical Case Reports
Dipeptidyl peptidase-4 inhibitors are oral antihyperglycemic medications often used as adjuncts to other antidiabetic agents to treat type 2 diabetes mellitus.
Alexa Moschella, Carly Kirshen
doaj   +1 more source